Vor Biopharma Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Vor Biopharma Inc. (VOR) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $3.08 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-03-30
- Vor Biopharma Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00.
- Vor Biopharma Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-09-30 was -$70.00K, a 108.42% decline year-over-year.
- Vor Biopharma Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-06-30 was -$163.00K, a 100.96% decline year-over-year.
- Vor Biopharma Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-03-31 was $270.00K, a 95.77% decline year-over-year.
- Vor Biopharma Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $3.08M.
- Vor Biopharma Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00.
- Vor Biopharma Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $23.38M, a 66688.57% increase from fiscal 2021.
- Vor Biopharma Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $35.00K, a 99.80% decline from fiscal 2020.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $3.08M 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $3.08M 10-Q · filed 2025-11-13 | |||||
| 2024-12-31 | $0.00 10-K · filed 2026-03-30 | |||||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-08 | |||||
| 2023-09-30 | -$70.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$233.00K derived: sum of 2 quarters · filed 2024-11-07 | $37.00K 10-Q · filed 2024-11-07 | -$794.00K derived: sum of 4 quarters · filed 2024-11-07 | ||
| 2023-06-30 | -$163.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $107.00K 10-Q · filed 2024-08-08 | -$724.00K derived: sum of 3 quarters · filed 2024-08-08 | $107.00K derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | $270.00K 10-Q · filed 2024-05-09 | -$561.00K derived: sum of 2 quarters · filed 2024-05-09 | $270.00K derived: sum of 3 quarters · filed 2024-05-09 | $17.27M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2022-12-31 | -$831.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $0.00 derived: sum of 2 quarters · filed 2024-03-20 | $17.00M derived: sum of 3 quarters · filed 2024-03-20 | $23.38M 10-K · filed 2024-03-20 | ||
| 2022-09-30 | $831.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $17.83M derived: sum of 2 quarters · filed 2023-11-07 | $24.21M 10-Q · filed 2023-11-07 | $32.29M 10-Q · filed 2022-11-10 | $24.21M derived: sum of 4 quarters · filed 2023-11-07 | |
| 2022-06-30 | $17.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $23.38M 10-Q · filed 2023-08-10 | $31.90M 10-Q · filed 2022-08-11 | $23.38M derived: sum of 3 quarters · filed 2023-08-10 | $23.38M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | $6.38M 10-Q · filed 2023-05-11 | $6.38M derived: sum of 2 quarters · filed 2023-05-11 | $6.38M derived: sum of 3 quarters · filed 2023-05-11 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $0.00 derived: sum of 2 quarters · filed 2023-03-23 | $35.00K 10-K · filed 2023-03-23 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $35.00K 10-Q · filed 2022-11-10 | ||||
| 2021-06-30 | $35.00K 10-Q · filed 2022-08-11 | |||||
| 2020-12-31 | $17.90M 10-K · filed 2022-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |